8TRS

Structure of the EphA2 CRD bound to FabS1CE_C1, trigonal form


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.90 Å
  • R-Value Free: 0.214 
  • R-Value Work: 0.180 
  • R-Value Observed: 0.182 

wwPDB Validation   3D Report Full Report


This is version 1.1 of the entry. See complete history


Literature

Engineered antigen-binding fragments for enhanced crystallization of antibody:antigen complexes.

Bruce, H.A.Singer, A.U.Filippova, E.V.Blazer, L.L.Adams, J.J.Enderle, L.Ben-David, M.Radley, E.H.Mao, D.Y.L.Pau, V.Orlicky, S.Sicheri, F.Kurinov, I.Atwell, S.Kossiakoff, A.A.Sidhu, S.S.

(2024) Protein Sci 33: e4824-e4824

  • DOI: https://doi.org/10.1002/pro.4824
  • Primary Citation of Related Structures:  
    8T58, 8T6I, 8T7F, 8T7G, 8T7I, 8T8I, 8T9Y, 8TRS, 8TRT, 8TS5

  • PubMed Abstract: 

    The atomic-resolution structural information that X-ray crystallography can provide on the binding interface between a Fab and its cognate antigen is highly valuable for understanding the mechanism of interaction. However, many Fab:antigen complexes are recalcitrant to crystallization, making the endeavor a considerable effort with no guarantee of success. Consequently, there have been significant steps taken to increase the likelihood of Fab:antigen complex crystallization by altering the Fab framework. In this investigation, we applied the surface entropy reduction strategy coupled with phage-display technology to identify a set of surface substitutions that improve the propensity of a human Fab framework to crystallize. In addition, we showed that combining these surface substitutions with previously reported Crystal Kappa and elbow substitutions results in an extraordinary improvement in Fab and Fab:antigen complex crystallizability, revealing a strong synergistic relationship between these sets of substitutions. Through comprehensive Fab and Fab:antigen complex crystallization screenings followed by structure determination and analysis, we defined the roles that each of these substitutions play in facilitating crystallization and how they complement each other in the process.


  • Organizational Affiliation

    School of Pharmacy, University of Waterloo, Waterloo, Canada.


Macromolecules
Find similar proteins by:  (by identity cutoff)  |  3D Structure
Entity ID: 1
MoleculeChains Sequence LengthOrganismDetailsImage
S1CE variant of Fab C1 heavy chain222Homo sapiensMutation(s): 0 
Entity Groups  
Sequence Clusters30% Identity50% Identity70% Identity90% Identity95% Identity100% Identity
Sequence Annotations
Expand
  • Reference Sequence
Find similar proteins by:  (by identity cutoff)  |  3D Structure
Entity ID: 2
MoleculeChains Sequence LengthOrganismDetailsImage
S1CE variant of Fab C1 light chainB [auth G]215Homo sapiensMutation(s): 0 
Entity Groups  
Sequence Clusters30% Identity50% Identity70% Identity90% Identity95% Identity100% Identity
Sequence Annotations
Expand
  • Reference Sequence
Find similar proteins by:  (by identity cutoff)  |  3D Structure
Entity ID: 3
MoleculeChains Sequence LengthOrganismDetailsImage
Ephrin type-A receptor 2C [auth D]132Homo sapiensMutation(s): 0 
Gene Names: EPHA2ECK
EC: 2.7.10.1
UniProt & NIH Common Fund Data Resources
Find proteins for P29317 (Homo sapiens)
Explore P29317 
Go to UniProtKB:  P29317
PHAROS:  P29317
GTEx:  ENSG00000142627 
Entity Groups  
Sequence Clusters30% Identity50% Identity70% Identity90% Identity95% Identity100% Identity
UniProt GroupP29317
Sequence Annotations
Expand
  • Reference Sequence
Small Molecules
Ligands 4 Unique
IDChains Name / Formula / InChI Key2D Diagram3D Interactions
PEG
Query on PEG

Download Ideal Coordinates CCD File 
AA [auth G]
CA [auth G]
GA [auth G]
K [auth A]
L [auth A]
AA [auth G],
CA [auth G],
GA [auth G],
K [auth A],
L [auth A],
Y [auth G],
Z [auth G]
DI(HYDROXYETHYL)ETHER
C4 H10 O3
MTHSVFCYNBDYFN-UHFFFAOYSA-N
EDO
Query on EDO

Download Ideal Coordinates CCD File 
BA [auth G]
D [auth A]
DA [auth G]
E [auth A]
EA [auth G]
BA [auth G],
D [auth A],
DA [auth G],
E [auth A],
EA [auth G],
F [auth A],
FA [auth G],
G [auth A],
H [auth A],
HA [auth G],
I [auth A],
IA [auth G],
J [auth A],
M [auth A],
N [auth A],
RA [auth D],
V [auth G],
W [auth G],
X [auth G]
1,2-ETHANEDIOL
C2 H6 O2
LYCAIKOWRPUZTN-UHFFFAOYSA-N
CL
Query on CL

Download Ideal Coordinates CCD File 
JA [auth G]
KA [auth G]
LA [auth G]
MA [auth G]
NA [auth G]
JA [auth G],
KA [auth G],
LA [auth G],
MA [auth G],
NA [auth G],
O [auth A],
OA [auth G],
P [auth A],
PA [auth G],
Q [auth A],
QA [auth G],
R [auth A],
S [auth A],
SA [auth D],
T [auth A],
TA [auth D],
U [auth A]
CHLORIDE ION
Cl
VEXZGXHMUGYJMC-UHFFFAOYSA-M
NA
Query on NA

Download Ideal Coordinates CCD File 
UA [auth D]SODIUM ION
Na
FKNQFGJONOIPTF-UHFFFAOYSA-N
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.90 Å
  • R-Value Free: 0.214 
  • R-Value Work: 0.180 
  • R-Value Observed: 0.182 
  • Space Group: P 32 2 1
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 71.376α = 90
b = 71.376β = 90
c = 235.014γ = 120
Software Package:
Software NamePurpose
PHENIXrefinement
XDSdata reduction
Aimlessdata scaling
PHASERphasing

Structure Validation

View Full Validation Report



Entry History & Funding Information

Deposition Data


Funding OrganizationLocationGrant Number
Celgene CorporationUnited StatesOperating Contract
Bristol-Myers Squibb (BMS) ResearchCollaboration and Option Agreement

Revision History  (Full details and data files)

  • Version 1.0: 2023-11-22
    Type: Initial release
  • Version 1.1: 2024-01-10
    Changes: Database references